Numab Therapeutics and Kaken Pharmaceutical Enter Collaboration and Option Agreement for Multi-specific Antibody ND081 for Treatment of Inflammatory Bowel Disease
15. November 2024 04:30 ET
|
Numab Therapeutics AG; Kaken Pharmaceutical Co., Ltd.
Numab to receive R&D funding for the preclinical development of ND081 Kaken Pharmaceutical receives an option to in-license ND081 in certain Asian territories in exchange for funding global...
Immunology Biosimilars Market Research 2024-2030, Profiles of Key Players - F. Hoffmann-La Roche, Merck, Eli Lily,. Pfizer, Novartis, Teva, Boehringer Ingelheim, Celltrion, Samsungbioepis, Amgen
14. November 2024 07:14 ET
|
Research and Markets
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel,...
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
13. November 2024 08:06 ET
|
Organovo, Inc.
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel...
Tumor Necrosis Factor Inhibitor Drugs Market to hit USD 50 billion by 2032, says Global Market Insights Inc.
02. Oktober 2024 05:42 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Tumor Necrosis Factor Inhibitor Drugs Market size valued at USD 41.3 billion in 2023 and is projected to grow at a CAGR of 2.2% from...
Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs
24. September 2024 04:00 ET
|
AKAMPION
Schlieren, Zurich/Switzerland, September 24, 2024 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has...
Inflammatory Bowel Disease Digital Marketing Trends Report 2024: Highest Proportion of Traffic to Top Branded Patient IBD Websites Originated from Paid Sources, Followed by Organic Sources
06. September 2024 06:01 ET
|
Research and Markets
Dublin, Sept. 06, 2024 (GLOBE NEWSWIRE) -- The "Digital Marketing Trends in Inflammatory Bowel Disease - April 2024" report has been added to ResearchAndMarkets.com's offering. This report...
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
16. Juli 2024 08:05 ET
|
Organovo, Inc.
Organovo presented on the Company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA.
SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases
09. Juli 2024 02:00 ET
|
SciRhom GmbH
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary...
Global Fecal Calprotectin Test Market Size To Exceed USD 366.15 Million By 2033 | CAGR of 11.24%
22. Juni 2024 02:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , June 22, 2024 (GLOBE NEWSWIRE) -- The Global Fecal Calprotectin Test Market Size is to Grow from USD 126.15 Million in 2023 to USD 366.15 Million by 2033, at a CAGR of...
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
21. Mai 2024 08:05 ET
|
Organovo, Inc.
Poster presented at DDW2024 demonstrating the potential of the Company’s clinical-stage compound, FXR314, in combination with tofacitinib for treating IBD.